User login
Key clinical point: High PRR34 antisense RNA 1 (PRR34-AS1) expression was associated with poor chemotherapeutic response and prognosis in patients with acute myeloid leukemia (AML).
Major finding: Patients with high (n=42) vs low (n=41) expression of PRR34-AS1 had a significantly lower rate of complete remission (CR; 37.1% vs 72.7%; P = .004) and shorter overall survival (P = .002). PRR34-AS1 was an independent factor affecting CR in patients with whole AML (odds ratio [OR], 0.282; P = .032), non-acute promyelocytic leukemia-AML (OR, 0.253; P = .039), and cytogenetically normal AML (OR, 0.210; P = .033).
Study details: This study assessed PRR34-AS1 expression in 84 adult patients with newly diagnosed AML and 29 healthy controls.
Disclosures: This study was supported by the National Natural Science Foundation of China, Medical Innovation Team of Jiangsu Province, Zhenjiang Clinical Research Center of Hematology, Social Development Foundation of Zhenjiang, and Scientific Research Project of the Fifth 169 Project of Zhenjiang. The authors declared no conflicts of interest.
Source: Nan FY et al. Cancer Med. 2021 Jul 5. doi: 10.1002/cam4.4085.
Key clinical point: High PRR34 antisense RNA 1 (PRR34-AS1) expression was associated with poor chemotherapeutic response and prognosis in patients with acute myeloid leukemia (AML).
Major finding: Patients with high (n=42) vs low (n=41) expression of PRR34-AS1 had a significantly lower rate of complete remission (CR; 37.1% vs 72.7%; P = .004) and shorter overall survival (P = .002). PRR34-AS1 was an independent factor affecting CR in patients with whole AML (odds ratio [OR], 0.282; P = .032), non-acute promyelocytic leukemia-AML (OR, 0.253; P = .039), and cytogenetically normal AML (OR, 0.210; P = .033).
Study details: This study assessed PRR34-AS1 expression in 84 adult patients with newly diagnosed AML and 29 healthy controls.
Disclosures: This study was supported by the National Natural Science Foundation of China, Medical Innovation Team of Jiangsu Province, Zhenjiang Clinical Research Center of Hematology, Social Development Foundation of Zhenjiang, and Scientific Research Project of the Fifth 169 Project of Zhenjiang. The authors declared no conflicts of interest.
Source: Nan FY et al. Cancer Med. 2021 Jul 5. doi: 10.1002/cam4.4085.
Key clinical point: High PRR34 antisense RNA 1 (PRR34-AS1) expression was associated with poor chemotherapeutic response and prognosis in patients with acute myeloid leukemia (AML).
Major finding: Patients with high (n=42) vs low (n=41) expression of PRR34-AS1 had a significantly lower rate of complete remission (CR; 37.1% vs 72.7%; P = .004) and shorter overall survival (P = .002). PRR34-AS1 was an independent factor affecting CR in patients with whole AML (odds ratio [OR], 0.282; P = .032), non-acute promyelocytic leukemia-AML (OR, 0.253; P = .039), and cytogenetically normal AML (OR, 0.210; P = .033).
Study details: This study assessed PRR34-AS1 expression in 84 adult patients with newly diagnosed AML and 29 healthy controls.
Disclosures: This study was supported by the National Natural Science Foundation of China, Medical Innovation Team of Jiangsu Province, Zhenjiang Clinical Research Center of Hematology, Social Development Foundation of Zhenjiang, and Scientific Research Project of the Fifth 169 Project of Zhenjiang. The authors declared no conflicts of interest.
Source: Nan FY et al. Cancer Med. 2021 Jul 5. doi: 10.1002/cam4.4085.